Amicus Therapeutics, Inc.
FOLD
$9.13
$0.232.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 571.16M | 543.14M | 528.30M | 493.67M | 455.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 571.16M | 543.14M | 528.30M | 493.67M | 455.66M |
| Cost of Revenue | 55.03M | 51.07M | 52.94M | 49.43M | 46.10M |
| Gross Profit | 516.13M | 492.07M | 475.35M | 444.24M | 409.56M |
| SG&A Expenses | 338.14M | 327.18M | 323.38M | 306.95M | 297.50M |
| Depreciation & Amortization | 7.90M | 8.23M | 8.55M | 8.69M | 8.75M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 546.11M | 495.35M | 494.23M | 479.27M | 481.08M |
| Operating Income | 25.05M | 47.79M | 34.06M | 14.40M | -25.43M |
| Income Before Tax | -22.51M | -3.22M | -28.76M | -68.35M | -99.84M |
| Income Tax Expenses | 15.59M | 26.16M | 27.35M | 36.34M | 19.70M |
| Earnings from Continuing Operations | -38.10 | -29.37 | -56.11 | -104.69 | -119.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.10M | -29.37M | -56.11M | -104.69M | -119.54M |
| EBIT | 25.05M | 47.79M | 34.06M | 14.40M | -25.43M |
| EBITDA | 32.95M | 56.02M | 42.61M | 23.09M | -16.68M |
| EPS Basic | -0.12 | -0.10 | -0.19 | -0.35 | -0.40 |
| Normalized Basic EPS | -0.04 | 0.00 | -0.04 | -0.09 | -0.16 |
| EPS Diluted | -0.12 | -0.10 | -0.19 | -0.35 | -0.40 |
| Normalized Diluted EPS | -0.04 | 0.00 | -0.04 | -0.09 | -0.16 |
| Average Basic Shares Outstanding | 1.23B | 1.22B | 1.22B | 1.21B | 1.20B |
| Average Diluted Shares Outstanding | 1.23B | 1.22B | 1.22B | 1.21B | 1.20B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |